{"downloaded": true, "htmlmade": false, "full": {"id": "25624421", "source": "MED", "pmid": "25624421", "pmcid": "PMC4923738", "fullTextIdList": {"fullTextId": "PMC4923738"}, "doi": "10.3233/jpd-140507", "title": "Usefulness of Genetic Testing in PD and PD Trials: A Balanced Review.", "authorString": "Gasser T.", "authorList": {"author": {"fullName": "Gasser T", "firstName": "Thomas", "lastName": "Gasser", "initials": "T"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "2", "volume": "5", "journalIssueId": "2354319", "dateOfPublication": "2015", "monthOfPublication": "0", "yearOfPublication": "2015", "printPublicationDate": "2015-01-01", "journal": {"title": "Journal of Parkinson's disease", "ISOAbbreviation": "J Parkinsons Dis", "medlineAbbreviation": "J Parkinsons Dis", "NLMid": "101567362", "ISSN": "1877-7171", "ESSN": "1877-718X"}}, "pubYear": "2015", "pageInfo": "209-215", "abstractText": "An increasing proportion of the individual and population risk to develop Parkinson's disease (PD) can be explained by genetic variants of different effect strength, forming a continuum from rare high penetrance gain or loss of function mutations to relatively common genetic risk variants that only mildly modify disease risk. In the coming years, further advances in molecular genetic technologies, in particular the increasing use of next generation sequencing, is likely to generate a wealth of new knowledge about the genetic basis of PD. Although specific treatments for PD based on the underlying genetic etiology will probably not be available in the near future, genetic testing is therefore likely to play an increasing role, both in the counselling of individual patients and their families with respect to the expected disease course and recurrence risks, and in the stratification of patient groups in clinical trials. Thus, the usefulness of genetic testing strongly depends on question asked and needs to be considered within each particular setting.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["review-article", "Review", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Parkinson Disease", "meshQualifierList": {"meshQualifier": {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Risk Factors"}, {"majorTopic_YN": "N", "descriptorName": "Mutation"}, {"majorTopic_YN": "N", "descriptorName": "Clinical Trials as Topic"}, {"majorTopic_YN": "N", "descriptorName": "Genetic Testing", "meshQualifierList": {"meshQualifier": {"abbreviation": "TD", "qualifierName": "trends", "majorTopic_YN": "Y"}}}]}, "keywordList": {"keyword": ["Mutation", "Genetics", "Parkinson\u2019s Disease", "Risk Variant"]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.3233/JPD-140507"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC4923738"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC4923738?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "13", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by-nc", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2016-06-22", "dateOfCreation": "2015-01-28", "firstIndexDate": "2015-01-28", "fullTextReceivedDate": "2020-07-11", "dateOfRevision": "2018-11-13", "firstPublicationDate": "2015-01-01"}, "htmllinks": "https://europepmc.org/articles/PMC4923738", "abstract": "An increasing proportion of the individual and population risk to develop Parkinson's disease (PD) can be explained by genetic variants of different effect strength, forming a continuum from rare high penetrance gain or loss of function mutations to relatively common genetic risk variants that only mildly modify disease risk. In the coming years, further advances in molecular genetic technologies, in particular the increasing use of next generation sequencing, is likely to generate a wealth of new knowledge about the genetic basis of PD. Although specific treatments for PD based on the underlying genetic etiology will probably not be available in the near future, genetic testing is therefore likely to play an increasing role, both in the counselling of individual patients and their families with respect to the expected disease course and recurrence risks, and in the stratification of patient groups in clinical trials. Thus, the usefulness of genetic testing strongly depends on question asked and needs to be considered within each particular setting.", "Keywords": ["Mutation", "Genetics", "Parkinson\u2019s Disease", "Risk Variant"], "pdflinks": "https://europepmc.org/articles/PMC4923738?pdf=render", "journaltitle": "Journal of Parkinson's disease", "title": "Usefulness of Genetic Testing in PD and PD Trials: A Balanced Review."}